Lundbeck announces financial guidance for 2023 and mid-term financial targets that build on very strong 2022 performance
Valby, Denmark, February 7, 2023 - H. Lundbeck A/S (Lundbeck) announces the financial guidance for 2023 and medium-term targets following very strong financial performance in 2022, where record revenue of DKK 18.2 billion was reached. In 2023, Lundbeck will continue the global roll-out of Vyepti with around 15 launches. Additionally, Lundbeck plans to launch aripiprazole 2-month ready-to-use (RTU) long-acting injectable (LAI) for both treatment of schizophrenia and the maintenance treatment of bipolar I disorder and brexpiprazole for the significant unmet need for patients with agitation